Condition
Chloasma
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Withdrawn1
Recruiting1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06418568Not ApplicableRecruitingPrimary
Efficacy and Safety Trial of Using Ultra-Pulsed Shockwaves to Deliver Tranexamic Acid for the Treatment of Melasma
NCT03618277Not ApplicableWithdrawnPrimary
Identification of Biomarkers and Characterization of Melasma
NCT03585179Phase 3Unknown
Oral and Topical Tranexamic Acid for the Treatment of Melasma
Showing all 3 trials